Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $847,325 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme.
Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifsciences Ltd (ASX:ANR) CEO Steve Lydeamore To Present at the Pitt Street Research Life Sciences Conference
Anatara's CEO Steve Lydeamore has been invited to present at the Pitt Street Research Life Sciences Conference on the 28th November in Sydney. Any investors interested in attending these presentations are invited to reach out.
Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore is interviewed by ABN Newswire, and talks about the human trials as well as the product pipeline for next year.
As Anatara moves forward, the Board is confident in the knowledge that a substantial market opportunity for Detach(R) remains, with more pressure than ever on producers to reduce their antibiotic use and find suitable alternatives which minimise illnesses, such as scour, on farms.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the 10th Annual Australian Microcap Investment Conference, held in Melbourne, VIC.
Anatara Lifesciences CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead's new podcast series, "The Health Kick".
Forecast expenditure for the December 2019 quarter is anticipated to increase as the Company advances the development of its Gastrointestinal Reprogramming (GaRP) dietary supplement. A refund from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme is anticipated to be received in December 2019.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to report statistically significant efficacy data from its in vivo mouse studies and further positive in vitro proof of concept data for its Gastrointestinal ReProgramming (GaRP) product.
Anatara Lifesciences Ltd's (ASX:ANR) lead human health product, GaRP, is being developed to specifically target two human gastrointestinal (GI) disorders, Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), where there is a significant unmet medical need.
Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore recently spoke with experienced business writer, Tim Boreham, for his Dr Boreham's Crucible column which was published in Biotech Daily on Friday night and then reproduced in Stockhead across the weekend.